Dopamine agonists and Parkinson's disease.
The therapeutic use of dopamine agonists for Parkinson's disease, clinical guidelines for their introduction into antiparkinson regimens, and their range of adverse effects are reviewed. The role played by the dopaminomimetic ergots in elucidating dopamine receptor function, and laboratory methods that identify dopamine agonists, are also examined.
D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001058:Apomorphine / Q000627:therapeutic use; D001921:Brain / Q000187:drug effects; D001971:Bromocriptine / Q000627:therapeutic use; D004873:Ergolines / Q000627:therapeutic use; D004876:Ergot Alkaloids / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008090:Lisuride / Q000627:therapeutic use; D009474:Neurons / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy*; D010479:Pergolide; D010891:Piribedil / Q000627:therapeutic use; D011954:Receptors, Dopamine / Q000187:drug effects*
D000978:Antiparkinson Agents; D004873:Ergolines; D004876:Ergot Alkaloids; D011954:Receptors, Dopamine; D010479:Pergolide; D001971:Bromocriptine; D007980:Levodopa; C034945:6-ethyl-9-oxaergoline; D010891:Piribedil; D008090:Lisuride; D001058:Apomorphine; C031649:mesulergine